SRR8613807
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.530
- MYC_TARGETS_V1+0.450
- E2F_TARGETS+0.440
- G2M_CHECKPOINT+0.360
- INTERFERON_ALPHA_RESPONSE+0.330
- UNFOLDED_PROTEIN_RESPONSE+0.300
- PROTEIN_SECRETION+0.290
- DNA_REPAIR+0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.250
- MITOTIC_SPINDLE+0.220
Top 10 suppressed
- ANGIOGENESIS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- MYOGENESIS-0.360
- KRAS_SIGNALING_UP-0.340
- COAGULATION-0.300
- PANCREAS_BETA_CELLS-0.300
- UV_RESPONSE_DN-0.300
- HEDGEHOG_SIGNALING-0.250
- IL2_STAT5_SIGNALING-0.250
- ADIPOGENESIS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-58-A46M-01A-11R-A24H-07 | — | cohortSQ2 | 0.870 |
| 2 | SRR8613729 | — | E | 0.855 |
| 3 | SRR650180 | — | — | 0.851 |
| 4 | TCGA-91-6836-01A-21R-1858-07 | — | cohortA1 | 0.836 |
| 5 | 78699d1d-aa39-473a-b3ea-24164d3a443c | — | — | 0.828 |
| 6 | 04e3aeba-c9bd-483d-9484-5ecc0e64a054 | — | — | 0.823 |
| 7 | 504282dd-4fef-4f70-a709-6a545d00a263 | — | — | 0.821 |
| 8 | SRR8518323 | — | E | 0.819 |
| 9 | MNG95 | — | — | 0.819 |
| 10 | SRR6013511 | — | cohortSQ1 | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.530 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.140 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.070 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.060 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |